UNITED STATES SECURITIES AND EXCHANGE ~~COMMISSION Washington~~COMMISSIONWashington, D.C. 20549

FORM 8-K

CURRENT ~~REPORT~~REPORTPursuant ~~Pursuant~~ to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~August 428, ~~2012~~ 2012

MABCURE INC. (Exact ~~name~~ name of registrant as specified in its charter)

Nevada (State or other jurisdiction of incorporation)

333-141131 (Commission File Number)

20-4907813 (IRS Employer Identification No.)

~~228~~21 ~~Park~~Sparrow ~~Ave~~Circle White ~~S #15740New York~~Plains, NY ~~10003~~ 10605 (Address of principal executive offices and Zip Code)

(845) 591-3144 (Registrant's ~~telephone~~ telephone number, including area code)

~~____________________________________________________~~(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Item 5.02

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

On ~~April~~August 1828, 2012, the Board of Directors of the Registrant approved the appointment of MsDr.Charles ~~Vered~~T. ~~Caplan~~Tackney to its Board of Directors.

MsDr. ~~Caplan,~~Charles ~~age~~T. 43Tackney, ~~CEO~~Ph.D., ofcurrently ~~Kamedis~~the ~~Ltd.~~company's Chief Scientific Officer (CSO), ~~BIC~~is ~~Inc.~~a scientific and ~~Pbd~~Business ~~Ltd. From~~leader ~~2008~~with todiverse experience ~~2012,~~in ~~she~~clinical ~~served~~medicine asand ~~CEO~~new oftechnology ~~Kamedis Ltd~~development., aHis ~~derma-cosmetics company~~background ~~focused~~and onexpertise ~~utilizing~~span ~~plant~~the ~~extracts~~areas ~~for~~of ~~dermatology~~molecular ~~purposes~~biology, ~~and~~biotechnology ~~from 2004 to~~and ~~2007,~~diagnostics. MsDr. ~~Caplan~~Tackney has served as ~~CEO~~the ofChief ~~GammaCan~~Scientific ~~International~~Officer of NeuroMark Genomics, Inc., aand ~~pharmaceutical company~~prior ~~focused~~to onthat, ~~the~~he ~~use~~worked ofin ~~immunoglobulins~~various positions for the ~~treatment~~Ortho Clinical Diagnostics unit of ~~cancer.~~Johnson ~~From~~& Johnson, including, Director of the ~~1998~~Diagnostic toBiomarker ~~2008~~Evaluation Group, ~~Ms.~~Scientific ~~Caplan~~Director ~~was~~of anAdvanced ~~active~~Research & ~~entrepreneur~~Technology inAssessment World Wide, as well as Director of the ~~life-science~~Prion Research ~~arena~~Group. ~~Ms.~~ ~~Caplan~~He ~~earned~~was athe ~~B.Sc.~~Director inof ~~mechanical~~Molecular ~~engineering~~Biology ~~from~~for ImClone Systems at the ~~Technion~~time of its founding, and was a Damon Runyon Post-Doctoral Fellow at the MColumbia University Hammer Cancer Center.~~Sc.~~ inHe ~~bio-medical~~received ~~engineering~~his Ph.D. from ~~Tel-Aviv~~the City University of New York.

In connection with Ms. Caplan's appointment to the Board of Directors, the Registrant entered into an at-will director’s agreement with Ms. Caplan, the terms of which include the following:

Ms. Caplan will receive $4,000 annually for her services as Director.

Ms. Caplan will receive an additional annual payment of $8,000 if she serves as a member of a committee of the Board.

The Registrant undertook to grant Ms. Caplan five year stock options to purchase 120,000 shares of the Registrant’s common stock at an exercise price of $0.05 per share.

There are no family relationships between any of our Directors or executive officers.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MABCURE INC. (Registrant) By: /s/Dov ~~Dr.~~Weinberg ~~Amnon~~Dov ~~Gonenne~~Weinberg ~~Dr. Amnon Gonenne President and~~ Chief ~~Executive~~Financial Officer

Date: ~~May~~August 429 , 2012

Filing Compare · MABCURE INC.